Victory Capital Management Inc. Purchases 89,530 Shares of Biogen Inc. $BIIB

Key Points

• Victory Capital Management increased its Biogen stake by 72.5%, buying 89,530 shares to own 212,962 shares worth $29.83 million (about 0.15% of the company), and institutional investors now hold roughly 87.93% of the stock.
• Biogen beat quarterly estimates with $1.99 EPS (vs. $1.61 est.) and $2.28B revenue, set FY2026 guidance of 15.25–16.25 EPS (analysts expect 15.83), yet shares were down about 1.7% amid profit‑taking.

Victory Capital Management Inc. grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 72.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 212,962 shares of the biotechnology company's stock after buying an additional 89,530 shares during the quarter. Victory Capital Management Inc. owned 0.15% of Biogen worth $29,832,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Focus Partners Advisor Solutions LLC grew its position in Biogen by 17.0% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 7,387 shares of the biotechnology company's stock valued at $1,134,000 after acquiring an additional 1,076 shares during the last quarter. Elo Mutual Pension Insurance Co boosted its stake in shares of Biogen by 20.5% during the third quarter. Elo Mutual Pension Insurance Co now owns 21,602 shares of the biotechnology company's stock valued at $3,026,000 after purchasing an additional 3,668 shares during the period. Huntington National Bank boosted its stake in shares of Biogen by 11.5% during the third quarter. Huntington National Bank now owns 2,285 shares of the biotechnology company's stock valued at $320,000 after purchasing an additional 235 shares during the period. Accredited Wealth Management LLC grew its holdings in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 185 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Biogen by 1.8% in the third quarter. Handelsbanken Fonder AB now owns 99,316 shares of the biotechnology company's stock worth $13,912,000 after purchasing an additional 1,715 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present new spinal muscular atrophy (SMA) data, including long‑term high‑dose nusinersen results and Phase 1b salanersen data as Phase 3 studies begin — news that supports the company’s SMA pipeline and could boost long‑term revenue potential if later trials read out favorably. Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• Positive Sentiment: The New England Journal of Medicine published first data suggesting disease‑modifying potential for zorevunersen (Stoke Therapeutics collaboration) in Dravet syndrome, supporting the ongoing global Phase 3 EMPEROR study — a favorable scientific read that can increase confidence in Biogen’s partnered pipeline assets. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
• Positive Sentiment: Proposed legislation (H.R. 7336, the ALS Better Care Act) would expand Medicare coverage and payments for ALS‑related services and incentivize clinical trial participation — a policy tailwind that could improve access and reimbursement for ALS therapies and indirectly benefit Biogen’s neurology franchise. New Bill: Representative Janice D. Schakowsky introduces H.R. 7336: ALS Better Care Act
• Neutral Sentiment: Analyst / investor pieces and fund letters have highlighted Biogen as an attractive long‑term holding (coverage in InsiderMonkey/Yahoo) — supportive for investor interest but not an immediate catalyst. What Makes Biogen (BIIB) an Attractive Long-Term Holding?
• Neutral Sentiment: Recent short‑interest reports show anomalous data (zero shares / NaN increases and a days‑to‑cover of 0.0), indicating reporting noise rather than a clear short‑selling pressure signal — treat these items as unreliable until clarified. (Internal short‑interest entries)
• Negative Sentiment: Despite positive pipeline and data releases, shares are down today — likely reflecting profit‑taking after recent gains, thin trading (volume below recent average), and market focus on near‑term revenue/guidance rather than later‑stage trial data. No new negative company‑specific regulatory or financial disclosures were reported in the entries provided.

Biogen Trading Down 1.7%

Shares of NASDAQ BIIB opened at $184.87 on Monday. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41. The business has a fifty day moving average price of $183.08 and a 200 day moving average price of $165.46. The stock has a market capitalization of $27.13 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.47 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts' consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the company posted $3.44 earnings per share. The firm's revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BIIB shares. Guggenheim lifted their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a "buy" rating in a report on Monday, February 9th. Royal Bank Of Canada raised their target price on shares of Biogen from $217.00 to $233.00 and gave the stock an "outperform" rating in a research report on Monday, February 9th. Jefferies Financial Group lifted their price target on shares of Biogen from $190.00 to $210.00 and gave the company a "buy" rating in a research note on Friday, November 28th. TD Cowen boosted their price target on Biogen from $175.00 to $215.00 and gave the company a "buy" rating in a report on Monday, February 9th. Finally, Stifel Nicolaus increased their price objective on Biogen from $202.00 to $214.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $205.04.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.